Global Drug Development Database with 1,000 Pharmaceutical Assets

A sample of 1,000 pharmaceutical assets across all development stages, enriched with early-phase compounds to support AI research. It tracks regulatory milestones including New Molecular Entity and First-in-Class designations. The dataset was created by PatSnap and was last updated on 2026-04-22.

Use Cases

• Predicting drug development outcomes based on phase-enriched sampling.
• Analyzing trends in regulatory designations like NME and QIDP.
• Training models to identify patterns in early-stage (Preclinical, Phase I, II) compounds.

Strengths

• Contains 1,000 pharmaceutical assets.
• Deliberately enriched with early-phase compounds (Preclinical, Phase I, Phase II).
• Tracks specific regulatory milestones (NME, First-in-Class, QIDP).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

PatSnap

Freshness

Last updated 2026-04-22 09:17:58; freshness should be verified.